ERBB2 and breast cancer: Among the five different subtypes, two prominent challenges have emerged in the management of breast cancer: resistance to endocrine therapy in estrogen receptor ER(+) tumors [2] and heterogeneous response to anti-HER2 therapy in HER2(+) tumors [3].